Tharimmune (THAR) COO/Director granted 5,000 options at $3.075
Tharimmune (THAR) reported an insider equity award.
Rhea-AI Filing Summary
Tharimmune (THAR) reported an insider equity award. A director and COO received a stock option grant for 5,000 derivative securities on 11/03/2025 with an exercise price of $3.075 per share. The option is first exercisable on 11/03/2025 and expires on 11/03/2035.
Following the reported transaction, the insider beneficially owned 55,000 derivative securities. The filing lists the ownership form as direct and records the transaction code as an acquisition.
Positive
- None.
Negative
- None.
Insights
Routine Form 4: 5,000 options granted at $3.075.
The filing records a grant of stock options to a Tharimmune director and COO for $3.075 per share, covering 5,000 underlying common shares. The options are exercisable starting 11/03/2025 and expire on 11/03/2035, consistent with standard equity compensation.
After the grant, the insider reports 55,000 derivative securities beneficially owned. This is administrative in nature; actual impact depends on future exercises and market conditions, which are not addressed in the excerpt.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 5,000 | $0.00 | $0.00 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Tharimmune (THAR) disclose in this Form 4?
What is the exercise price and term of the THAR options?
How many derivative securities does the insider own after the transaction?
What was the transaction code for the THAR insider grant?
Is the ownership direct or indirect?
AI-generated analysis. How Rhea-AI works. Not financial advice.